ClinicalTrials.gg
CompletedNCT00633880NOH302Updated May 20, 2014Results posted

Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH)

A Phase 3 interventional study of Placebo and Droxidopa in Symptomatic Neurogenic Orthostatic Hypotension (NOH), Non-diabetic Neuropathy and Primary Autonomic Failure, sponsored by Chelsea Therapeutics. Completed at 54 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-05-20.

Sponsored by Chelsea Therapeutics (part of H. Lundbeck A/S) · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
181
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 15 studies testing droxidopa in Hypotension, Orthostatic — 2 open to participants now, 2 under way, none of them phase 3. Droxidopa · Hypotension, Orthostatic.

Enrollment
3rd of 14
181 · median 28
Started
2008
with 2 others
Phase 3
5 of 15
none open now
Registered
3rd of 15
by date
Lead sponsor
6 of 15
Chelsea Therapeutics

Among the 15 studies testing droxidopa in Hypotension, Orthostatic, this one is the 3rd largest by enrollment of the 14 interventional ones that give a count, is one of 3 that started in 2008, is one of 5 in phase 3, and was the 3rd registered.

Hypotension, Orthostatic

159 studies on the registry are indexed under Hypotension, Orthostatic; 35 are open to participants now.

Browse Hypotension, Orthostatic studies →

Open to participants now

2 of the 15 studies testing droxidopa in Hypotension, Orthostatic are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About droxidopa

Droxidopa: first FDA approval 2014 (NORTHERA). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 23 Hypotension, Orthostatic studies recruiting now, 8 (35%) set no upper age limit and 8 (35%) stop at 75 or younger; 1 takes children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies testing droxidopa in Hypotension, Orthostatic, or all of them as a file.
02

Study summary

The purpose of this study is to see whether droxidopa is effective in treating symptoms of neurogenic orthostatic hypotension in patients with Primary Autonomic Failure (Pure Autonomic Failure, Multiple System Atrophy, Parkinson's Disease), Non-diabetic neuropathy, or Beta Hydroxylase deficiency.

Read the detailed description

Systolic blood pressure is transiently and minimally decreased in healthy individuals upon standing. Normal physiologic feedback mechanisms work through neurally-mediated pathways to maintain the standing blood pressure, and thus maintain adequate cerebral perfusion. The compensatory mechanisms that regulate blood pressure upon standing are dysfunctional in subjects with orthostatic hypotension (OH), a condition that may lead to inadequate cerebral perfusion with accompanying symptoms of syncope, dizziness or lightheadedness, unsteadiness and blurred or impaired vision, among other symptoms.

The autonomic nervous system has a central role in the regulation of blood pressure. Primary Autonomic Failure is manifested in a variety of syndromes. Orthostatic hypotension is a usual presenting symptom. Primary Autonomic Failure may be the primary diagnosis, and classifications include pure autonomic failure (PAF), also called idiopathic orthostatic hypotension (Bradbury-Eggleston syndrome) autonomic failure with multiple system atrophy (Shy-Drager syndrome) and also Parkinson's disease. Regardless of the primary condition, autonomic dysfunction underlies orthostatic hypotension.

Orthostatic hypotension may be a severely disabling condition which can seriously interfere with the quality of life of afflicted subjects. Currently available therapeutic options provide some symptomatic relief in a subset of subjects, but are relatively ineffective and are often accompanied by severe side effects that limit their usefulness. Support garments (tight-fitting leotard) may prove useful in some subjects, but is difficult to don without family or nursing assistance, especially for older subjects. Midodrine, fludrocortisone, methylphenidate, ephedrine, indomethacin and dihydroergotamine are among some of the pharmacological interventions that have been used to treat orthostatic hypotension, although only midodrine is specifically approved for this indication. The limitations of these currently available therapeutic options, and the incapacitating nature and often progressive downhill course of disease, point to the need for an improved therapeutic alternative.

The current withdrawal design study will measure the efficacy of droxidopa on symptoms of neurogenic orthostatic hypotension in patients randomized to continued droxidopa treatment versus placebo, following 14 days of double-blind treatment.

droxidopa

droxidopa [also, known as L-threo-3,4-dihydroxyphenylserine, L-threo-DOPS, or L-DOPS] is the International non-proprietary name (INN) for a synthetic amino acid precursor of norepinephrine (NE), which was originally developed by Sumitomo Pharmaceuticals Co., Limited, Japan. It has been approved for use in Japan since 1989. Droxidopa has been shown to improve symptoms of orthostatic hypotension that result from a variety of conditions including Shy Drager syndrome (Multiple System Atrophy), Pure Autonomic Failure, and Parkinson's disease. There are four stereoisomers of DOPS; however, only the L-threo-enantiomer (droxidopa) is biologically active.

The exact mechanism of action of droxidopa in the treatment of symptomatic NOH has not been precisely defined; however, its NE replenishing properties with concomitant recovery of decreased noradrenergic activity are considered to be of major importance.

Droxidopa has been marketed in Japan since 1989. Data from clinical studies and post-marketing surveillance programs conducted in Japan show that the most commonly reported adverse drug reactions with droxidopa are increased blood pressure, nausea, and headache. In clinical studies, the prevalence and severity of droxidopa adverse effects appear to be similar to those reported by the placebo control arm.

03

Conditions studied

  • Symptomatic Neurogenic Orthostatic Hypotension (NOH)
  • Non-diabetic Neuropathy
  • Primary Autonomic Failure
  • Dopamine Beta Hydroxylase Deficiency

Keywords

  • NOH
  • Neurogenic Orthostatic Hypotension
  • Orthostatic hypotension
  • PAF
  • Pure Autonomic Failure
  • MSA
  • Multiple System Atrophy
  • Neuropathy
  • Autonomic Failure
  • Parkinson
  • Dopamine Deficiency
  • Dopamine
  • Droxidopa
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

PATIENT INCLUSION CRITERIA:

  • Male or female and aged 18 years or over;
  • Clinical diagnosis of orthostatic hypotension associated with Primary Autonomic Failure (PD, MSA and PAF), Dopamine Beta Hydroxylase Deficiency or Non-Diabetic Autonomic Neuropathies;
  • A documented fall in systolic blood pressure of at least 20 mmHg, or in diastolic blood pressure of at least 10 mmHg, within 3 minutes after standing;
  • Provide written to participate in the study and understand that they may withdraw their consent at any time without prejudice to their future medical care.

MAIN PATIENT EXCLUSION CRITERIA:

  • Taking ephedrine or midodrine; Patients taking ephedrine or midodrine may enroll after a minimum 7 day ;
  • Taking anti-hypertensive medication;
  • Have a history of more than moderate alcohol consumption;
  • Women who are pregnant or lactating;
  • Have a history of closed angle glaucoma;
  • Have pre-existing sustained severe hypertension (BP > 180/110 mmHg in the sitting position);
  • Have atrial fibrillation or, in the investigator's opinion, have any other significant cardiac arrhythmia;
  • In the investigator's opinion, have any other significant systemic, hepatic, cardiac or renal illness;
  • Have diabetes mellitus or insipidus;
  • Have a known or suspected ;
  • Have known gastrointestinal illness or other gastrointestinal disorder that may, in the investigator's opinion, affect the absorption of study drug;
  • In the investigator's opinion, have abnormalities on clinical examination or laboratory testing;
  • Have a serum creatinine level > 130 µmol/L;
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
181 participants (actual)

Study arms

  • Experimental
    Droxidopa

    Double-blind

    Drug: Droxidopa

  • Placebo comparator
    Placebo

    Double-blind

    Drug: Placebo

Interventions

  • DrugPlacebo

    100 mg, oral, three times per day 200 mg, oral, three times per day 300 mg, oral, three times per day 400 mg, oral, three times per day 500 mg, oral, three times per day 600 mg, oral, three times per day

  • 100 mg, oral, three times per day 200 mg, oral, three times per day 300 mg, oral, three times per day 400 mg, oral, three times per day 500 mg, oral, three times per day 600 mg, oral, three times per day

    Also known as: L-DOPS, L-threo-DOPS, Northera

06

What researchers measure

Primary outcomes

  1. Change in Dizziness/ Lightheadedness/ Feeling Faint/ or Feeling Like You Might Blackout (OHSA Item 1)

    OHSA item 1 scale range: 0 (none) -10 (worst), likert scale. Change: score at end of study minus score at randomization. In this withdrawal design, a positive score indicates worsening during the double-blind randomized phase relative to value at randomization (on open-label drug) .

    Time frame: 14 days

Secondary outcomes

  1. Change in Fatigue (OHSA Item 4)

    OHSA item 4 scale range: 0 (none) -10 (worst), likert scale. Change: score at end of study minus score at randomization. In this withdrawal design, a positive score indicates worsening during the double-blind randomized phase relative to value at randomization (on open-label drug) .

    Time frame: 14 days

  2. Change in Weakness (OHSA Item 3)

    OHSA item 3 scale range: 0 (none) -10 (worst), likert scale. Change: score at end of study minus score at randomization. In this withdrawal design, a positive score indicates worsening during the double-blind randomized phase relative to value at randomization (on open-label drug) .

    Time frame: 14 days

  3. Change in Vision (OHSA Item 2)

    OHSA item 2 scale range: 0 (none) -10 (worst), likert scale. Change: score at end of study minus score at randomization. In this withdrawal design, a positive score indicates worsening during the double-blind randomized phase relative to value at randomization (on open-label drug) .

    Time frame: 14 days

  4. Change in Concentration (OHSA Item 5)

    OHSA item 5 scale range: 0 (none) -10 (worst), likert scale. Change: score at end of study minus score at randomization. In this withdrawal design, a positive score indicates worsening during the double-blind randomized phase relative to value at randomization (on open-label drug) .

    Time frame: 14 days

  5. Change in Head/Neck Discomfort (OHSA Item 6)

    OHSA item 6 scale range: 0 (none) -10 (worst), likert scale. Change: score at end of study minus score at randomization. In this withdrawal design, a positive score indicates worsening during the double-blind randomized phase relative to value at randomization (on open-label drug) .

    Time frame: 14 days

  6. Change in Ability to Conduct Activities of Daily Living Score (OHDAS Composite Score)

    The OHDAS scale is the average of four items: 1) Standing for a short time; 2) Standing for a long time; 3) Walking for a short time; and 4) Walking for a long time. Each asks the patient to rate their disease impact over the past week. Each item is scored on a Likert scale from 0 to 10, with 10 being the most severe. Change: score at end of study minus score at randomization. In this withdrawal design, a positive score indicates worsening during the double-blind randomized phase relative to value at randomization (on open-label drug) .

    Time frame: 14 days

  7. Change in Orthostatic Hypotension Symptom Assessment Score (OHSA Composite)

    The OHSA scale is the average of six items: 1) Dizziness, lightheadedness, feeling faint or feeling like you might black out; 2) Problems with vision; 3) Weakness; 4) Fatigue; 5) Trouble concentrating; and 6) Head/neck discomfort. Each asks the patient to rate their symptoms over the past week. Each item is scored on a Likert scale from 0 to 10, with 10 being the most severe. Change: score at end of study minus score at randomization. In this withdrawal design, a positive score indicates worsening during the double-blind randomized phase relative to value at randomization (on open-label drug) .

    Time frame: 14 days

  8. Change in Orthostatic Hypotension Symptom Scores Excluding Dizziness (OHSA Composite Items 2-6)

    OHSA composite scale (items 2-6) is the average of five OHSA items: 2) Problems with vision; 3) Weakness; 4) Fatigue; 5) Trouble concentrating; and 6) Head/neck discomfort. Each asks the patient to rate their symptoms over the past week. Each item is scored on a Likert scale from 0 to 10, with 10 being the most severe. Change: score at end of study minus score at randomization. In this withdrawal design, a positive score indicates worsening during the double-blind randomized phase relative to value at randomization (on open-label drug) .

    Time frame: 14 days

  9. Change in Systolic Blood Pressure (SBP) Measurements 3 Minutes Post Standing;

    Change: standing systolic blood pressure at end of study minus standing systolic blood pressure at randomization. In this withdrawal design, a negative score indicates worsening during the double-blind randomized phase relative to value at randomization (on open-label drug) .

    Time frame: 14 days

07

Results

Posted May 20, 2014

Participant flow

Open Label Titration
Participant flow — Open Label Titration
MilestoneOpen Label TitrationDroxidopaPlacebo
Started18100
Completed10100
Not completed8000
Withdrew: Lack of efficacy100
Withdrew: Adverse event1300
Withdrew: Treatment failure5500
Withdrew: Protocol violation600
Withdrew: Physician decision100
Withdrew: Withdrawal by subject400
Randomized Double Blind
Participant flow — Randomized Double Blind
MilestoneOpen Label TitrationDroxidopaPlacebo
Started05051
Completed05051
Not completed000

Outcome measures

PrimaryChange in Dizziness/ Lightheadedness/ Feeling Faint/ or Feeling Like You Might Blackout (OHSA Item 1)

OHSA item 1 scale range: 0 (none) -10 (worst), likert scale. Change: score at end of study minus score at randomization. In this withdrawal design, a positive score indicates worsening during the double-blind randomized phase relative to value at randomization (on open-label drug) .

Time frame:
14 days
Reported as:
Mean · units on a scale
Change in Dizziness/ Lightheadedness/ Feeling Faint/ or Feeling Like You Might Blackout (OHSA Item 1)
units on a scaleDroxidopaPlacebo
Change in Dizziness/ Lightheadedness/ Feeling Faint/ or Feeling Like You Might Blackout (OHSA Item 1)1.3 ± 2.751.9 ± 3.16
Statistical analysis
  • Droxidopa vs Placebo · Wilcoxon (Mann-Whitney) · p = 0.509 (Statistical analysis plan involved a hierarchical assessment of secondary endpoints to prevent inflation of type I errors. As the primary endpoint was not positive, statistical analysis was not performed on secondary endpoints.)
SecondaryChange in Fatigue (OHSA Item 4)

OHSA item 4 scale range: 0 (none) -10 (worst), likert scale. Change: score at end of study minus score at randomization. In this withdrawal design, a positive score indicates worsening during the double-blind randomized phase relative to value at randomization (on open-label drug) .

Time frame:
14 days
Reported as:
Mean · units on a scale
Change in Fatigue (OHSA Item 4)
units on a scaleDroxidopaPlacebo
Change in Fatigue (OHSA Item 4)0.7 ± 2.611.5 ± 2.72
SecondaryChange in Weakness (OHSA Item 3)

OHSA item 3 scale range: 0 (none) -10 (worst), likert scale. Change: score at end of study minus score at randomization. In this withdrawal design, a positive score indicates worsening during the double-blind randomized phase relative to value at randomization (on open-label drug) .

Time frame:
14 days
Reported as:
Mean · units on a scale
Change in Weakness (OHSA Item 3)
units on a scaleDroxidopaPlacebo
Change in Weakness (OHSA Item 3)0.3 ± 2.881.2 ± 2.70
SecondaryChange in Vision (OHSA Item 2)

OHSA item 2 scale range: 0 (none) -10 (worst), likert scale. Change: score at end of study minus score at randomization. In this withdrawal design, a positive score indicates worsening during the double-blind randomized phase relative to value at randomization (on open-label drug) .

Time frame:
14 days
Reported as:
Mean · units on a scale
Change in Vision (OHSA Item 2)
units on a scaleDroxidopaPlacebo
Change in Vision (OHSA Item 2)1.1 ± 2.790.8 ± 2.24
SecondaryChange in Concentration (OHSA Item 5)

OHSA item 5 scale range: 0 (none) -10 (worst), likert scale. Change: score at end of study minus score at randomization. In this withdrawal design, a positive score indicates worsening during the double-blind randomized phase relative to value at randomization (on open-label drug) .

Time frame:
14 days
Reported as:
Mean · units on a scale
Change in Concentration (OHSA Item 5)
units on a scaleDroxidopaPlacebo
Change in Concentration (OHSA Item 5)0.1 ± 2.740.9 ± 2.67
Post-hocChange in Orthostatic Hypotension Questionnaire Score (OHQ)

The OHQ is the average of two sub-scales, the Orthostatic Hypotension Symptom Assessment Scale (OHSA) and the Orthostatic Hypotension Daily Activities Scale (OHDAS). Each asks the patient to rate their symptoms or disease impact over the past week. The OHSA sub-scale is the average of six items: 1) Dizziness, lightheadedness, feeling faint or feeling like you might black out; 2) Problems with vision; 3) Weakness; 4) Fatigue; 5) Trouble concentrating; and 6) Head/neck discomfort. The OHDAS sub-scale is the average of four items: 1) Standing for a short time; 2) Standing for a long time; 3) Walking for a short time; and 4) Walking for a long time. Each item is scored on a Likert scale from 0 to 10, with 10 being the most severe. In this withdrawal design, a positive score indicates worsening during the double-blind randomized phase relative to value at randomization (on open-label drug) .

Time frame:
14 days
Reported as:
Mean · units on a scale
Change in Orthostatic Hypotension Questionnaire Score (OHQ)
units on a scaleDroxidopaPlacebo
Change in Orthostatic Hypotension Questionnaire Score (OHQ)0.11 ± 2.1761.22 ± 2.390
Statistical analysis
  • Droxidopa vs Placebo · Wilcoxon (Mann-Whitney) · p = 0.026
SecondaryChange in Head/Neck Discomfort (OHSA Item 6)

OHSA item 6 scale range: 0 (none) -10 (worst), likert scale. Change: score at end of study minus score at randomization. In this withdrawal design, a positive score indicates worsening during the double-blind randomized phase relative to value at randomization (on open-label drug) .

Time frame:
14 days
Reported as:
Mean · units on a scale
Change in Head/Neck Discomfort (OHSA Item 6)
units on a scaleDroxidopaPlacebo
Change in Head/Neck Discomfort (OHSA Item 6)-0.1 ± 2.451.2 ± 3.19
SecondaryChange in Ability to Conduct Activities of Daily Living Score (OHDAS Composite Score)

The OHDAS scale is the average of four items: 1) Standing for a short time; 2) Standing for a long time; 3) Walking for a short time; and 4) Walking for a long time. Each asks the patient to rate their disease impact over the past week. Each item is scored on a Likert scale from 0 to 10, with 10 being the most severe. Change: score at end of study minus score at randomization. In this withdrawal design, a positive score indicates worsening during the double-blind randomized phase relative to value at randomization (on open-label drug) .

Time frame:
14 days
Reported as:
Mean · units on a scale
Change in Ability to Conduct Activities of Daily Living Score (OHDAS Composite Score)
units on a scaleDroxidopaPlacebo
Change in Ability to Conduct Activities of Daily Living Score (OHDAS Composite Score)-0.24 ± 2.350.91 ± 2.50
SecondaryChange in Orthostatic Hypotension Symptom Assessment Score (OHSA Composite)

The OHSA scale is the average of six items: 1) Dizziness, lightheadedness, feeling faint or feeling like you might black out; 2) Problems with vision; 3) Weakness; 4) Fatigue; 5) Trouble concentrating; and 6) Head/neck discomfort. Each asks the patient to rate their symptoms over the past week. Each item is scored on a Likert scale from 0 to 10, with 10 being the most severe. Change: score at end of study minus score at randomization. In this withdrawal design, a positive score indicates worsening during the double-blind randomized phase relative to value at randomization (on open-label drug) .

Time frame:
14 days
Reported as:
Mean · units on a scale
Change in Orthostatic Hypotension Symptom Assessment Score (OHSA Composite)
units on a scaleDroxidopaPlacebo
Change in Orthostatic Hypotension Symptom Assessment Score (OHSA Composite)0.6 ± 2.271.35 ± 2.53
SecondaryChange in Orthostatic Hypotension Symptom Scores Excluding Dizziness (OHSA Composite Items 2-6)

OHSA composite scale (items 2-6) is the average of five OHSA items: 2) Problems with vision; 3) Weakness; 4) Fatigue; 5) Trouble concentrating; and 6) Head/neck discomfort. Each asks the patient to rate their symptoms over the past week. Each item is scored on a Likert scale from 0 to 10, with 10 being the most severe. Change: score at end of study minus score at randomization. In this withdrawal design, a positive score indicates worsening during the double-blind randomized phase relative to value at randomization (on open-label drug) .

Time frame:
14 days
Reported as:
Mean · units on a scale
Change in Orthostatic Hypotension Symptom Scores Excluding Dizziness (OHSA Composite Items 2-6)
units on a scaleDroxidopaPlacebo
Change in Orthostatic Hypotension Symptom Scores Excluding Dizziness (OHSA Composite Items 2-6)0.44 ± 2.291.07 ± 2.25
SecondaryChange in Systolic Blood Pressure (SBP) Measurements 3 Minutes Post Standing;

Change: standing systolic blood pressure at end of study minus standing systolic blood pressure at randomization. In this withdrawal design, a negative score indicates worsening during the double-blind randomized phase relative to value at randomization (on open-label drug) .

Time frame:
14 days
Reported as:
Mean · mmHg
Change in Systolic Blood Pressure (SBP) Measurements 3 Minutes Post Standing;
mmHgDroxidopaPlacebo
Change in Systolic Blood Pressure (SBP) Measurements 3 Minutes Post Standing;-7.6 ± 19.71-5.2 ± 26.83

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Droxidopa—0/50 (0%)4/50 (8%)
Placebo—1/51 (2%)11/51 (21.6%)
Open Label Phase—4/181 (2.2%)44/181 (24.3%)
Most frequent serious events
Most frequent serious events
EventDroxidopaPlaceboOpen Label Phase
Urinary tract infectionInfections and infestations0/501/510/181
Mental status changePsychiatric disorders0/501/510/181
Coronary artery diseaseCardiac disorders0/500/511/181
Cardiac failure congestiveCardiac disorders0/500/511/181
PneumoniaInfections and infestations0/500/511/181
leukopeniaBlood and lymphatic system disorders0/500/511/181
Orthostatic hypotensionVascular disorders0/500/511/181
Most frequent other events
Most frequent other events
EventDroxidopaPlaceboOpen Label Phase
FallInjury, poisoning and procedural complications1/506/519/181
HeadacheNervous system disorders2/504/5120/181
DizzinessNervous system disorders2/501/5115/181
FatigueGeneral disorders0/501/5110/181

Baseline characteristics

Age, Continuous
Age, Continuous(years)Not RandomizedDroxidopaPlaceboTotal
Mean69.5 ± 9.7463.1 ± 13.7666.6 ± 11.2566.9 ± 11.62
Sex: Female, Male
Sex: Female, Male(Participants)Not RandomizedDroxidopaPlaceboTotal
Female35201974
Male453032107
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Not RandomizedDroxidopaPlaceboTotal
American Indian or Alaska Native0011
Asian0112
Native Hawaiian or Other Pacific Islander0000
Black or African American0000
White804949178
More than one race0000
Unknown or Not Reported0000
Region of Enrollment
Region of Enrollment(participants)Not RandomizedDroxidopaPlaceboTotal
United States532532110
Canada89219
United Kingdom53210
Poland510823
Australia82616
New Zealand1113
Primary Clinical Diagnosis
Primary Clinical Diagnosis(participants)Not RandomizedDroxidopaPlaceboTotal
Parkinson's Disease38212382
Multiple System Atrophy21171351
Pure Autonomic Failure1881036
Dopamine Beta-Hydroxylase Deficiency0011
Non-Diabetic Autonomic Neuropathy2237
Other1214
08

Study locations

54 sites
  • University of Alabama at Birmingham
    Birmingham, Alabama 35233, United States
  • Dedicated Clinical Research
    Litchfield Park, Arizona 85340, United States
  • Xenoscience Inc.
    Phoenix, Arizona 85004, United States
  • Sun Health Research Institute
    Sun City, Arizona 85351, United States
  • The Parkinson's and Movement Disorders Institute
    Fountain Valley, California 92708, United States
  • Pacific Neuroscience Medical Group
    Oxnard, California 93030, United States
  • The Parkinson's Institute
    Sunnyvale, California 94085, United States
  • Electrophysiology Associates
    Colorado Springs, Colorado 80910, United States
  • Parkinson's Disease & Movment Disorder Center
    Boca Raton, Florida 33486, United States
  • Southeastern Integrated Medical
    Gainesville, Florida 32607, United States
  • Mayo Jacksonville Florida Department of Neurology
    Jacksonville, Florida 32224, United States
  • University of Miami
    Miami, Florida 33136, United States
  • University of South Florida
    Tampa, Florida 33606, United States
  • Medical Associates of North Georgia
    Canton, Georgia 30114, United States
  • Saint Mary of Nazareth Hospital Center
    Chicago, Illinois 60622, United States
  • North Chicago VA Medical Center
    North Chicago, Illinois 60064, United States
  • Indiana Medical Research
    Elkhart, Indiana 46514, United States
  • JWM Neurology
    Indianapolis, Indiana 46237, United States
  • Kansas City Bone and Joint, PA
    Overland Park, Kansas 66211, United States
  • University of Louisville
    Louisville, Kentucky 40202, United States
  • University of Maryland
    Baltimore, Maryland 21201, United States
  • Beth Israel Deaconess Medical Center
    Boston, Massachusetts 02215, United States
  • University of Massachusetts Worcester
    Worcester, Massachusetts 01655, United States
  • Henry Ford Health System
    Southfield, Michigan 48034, United States
  • Mayo Clinic Rochester
    Rochester, Minnesota 55905, United States
  • Washington University Medical Center
    St. Louis, Missouri 63110, United States
  • New Jersey Neuroscience Institute
    Edison, New Jersey 08818, United States
  • Kingston Neurological Associates, PC
    Kingston, New York 12401, United States
  • NYU Medical Center
    New York City, New York 10016, United States
  • Columbia University
    New York, New York 10032, United States
  • University of Rochester
    Rochester, New York 14618, United States
  • Duke University Medical Center
    Durham, North Carolina 27705, United States
  • Wake Forest University
    Winston Salem, North Carolina 27157, United States
  • University of Cincinnati
    Cincinnati, Ohio 45267, United States
  • University Hospitals Case Medical Center
    Cleveland, Ohio 44106, United States
  • Cleveland Clinic
    Cleveland, Ohio 44195, United States
  • COR Clinical Research, LLC
    Oklahoma City, Oklahoma 73103, United States
  • The Oregon Clinic
    Portland, Oregon 97213, United States
  • Vanderbilt University
    Nashville, Tennessee 37212, United States
  • Jacinto Medical Group, PA
    Baytown, Texas 77521, United States
  • UT Southwestern Medical Center
    Dallas, Texas 75390-9036, United States
  • Scott & White Healthcare - Round Rock
    Round Rock, Texas 78665, United States
  • Scott & White Memorial Hospital & Clinic
    Temple, Texas 76508, United States
  • East Texas Medical Center
    Tyler, Texas 75701, United States
  • Royal Adelaide Hospital
    Adelaide, South Australia 5000, Australia
  • Baker Heart Research Institute
    Melbourne, Victoria 3004, Australia
  • Austin Hospital
    Heidelburg, 3084, Australia
  • McMaster University
    Hamilton, Ontario L8L2X2, Canada
  • Centre for Movement Disorders
    Markham, Ontario L6B1C9, Canada
  • Parkinson's & Neurodegenerative Disorders Clinic
    Ottawa, Ontario K1G4G3, Canada
  • SMBD Jewish General Hospital
    Montreal, Quebec H3T 1E2, Canada
  • Quebec Memory and Motor Skills Disorders Clinic
    Quebec, G1R 3X5, Canada
  • Auckland Hospital
    Grafton Auckland, Private Bag, New Zealand
  • Van der Veer Institute for Parkinson's Disease and Movement Disorders
    Christchurch, New Zealand
09

References and documents

Publications

  • Biaggioni I, Arthur Hewitt L, Rowse GJ, Kaufmann H. Integrated analysis of droxidopa trials for neurogenic orthostatic hypotension. BMC Neurol. 2017 May 12;17(1):90. doi: 10.1186/s12883-017-0867-5. PubMed 28494751 ↗
  • Francois C, Rowse GJ, Hewitt LA, Vo P, Hauser RA. Analysis of number needed to treat for droxidopa in patients with symptomatic neurogenic orthostatic hypotension. BMC Neurol. 2016 Aug 18;16(1):143. doi: 10.1186/s12883-016-0665-5. PubMed 27538531 ↗
  • Biaggioni I, Freeman R, Mathias CJ, Low P, Hewitt LA, Kaufmann H; Droxidopa 302 Investigators. Randomized withdrawal study of patients with symptomatic neurogenic orthostatic hypotension responsive to droxidopa. Hypertension. 2015 Jan;65(1):101-7. doi: 10.1161/HYPERTENSIONAHA.114.04035. Epub 2014 Oct 27. PubMed 25350981 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2008, a primary completion of Aug 2009 and a completion of Sep 2009. It does not say whether these dates are actual or estimated.

Results were first posted in May 2014, 4 years 9 months after primary completion. A results delay was requested in Jan 2012.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 5, 2008
First posted
Mar 12, 2008
Start
Jan 2008
Primary completionActual
Aug 2009
CompletionActual
Sep 2009
Results delay requested
Jan 25, 2012
Results first posted
May 20, 2014
Last update
May 20, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 20, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00633880
Collaborators
Chiltern International Inc.
Responsible party
Sponsor
First posted
Mar 12, 2008
Start date
Jan 2008
Primary completion
Aug 2009
Completion
Sep 2009
Results posted
May 20, 2014
Last update
May 20, 2014

Study contacts

Horacio Kaufmann, MD
principal investigator · NYU Langone Health
Christopher J Mathias, MD
principal investigator · Imperial School of Medicine
Roy Freeman, MD
principal investigator · Harvard Medicine School
Phillip A Low, MD
principal investigator · Mayo Foundation

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Droxidopa

Start the discussion